This book presents an overview of the current status of translating the RNAi cancer therapeutics in the clinic, a brief description of the biological barriers in drug delivery, and the roles of imaging in aspects of administration route, systemic circulation, and cellular barriers for the clinical translation of RNAi cancer therapeutics, and with partial content for discussing the safety concerns. It then focuses on imaging-guided delivery of RNAi therapeutics in preclinical development, including the basic principles of different imaging modalities, and their advantages and limitations for biological imaging. With growing number of RNAi therapeutics entering the clinic, various imaging methods will play an important role in facilitating the translation of RNAi cancer therapeutics from bench to bedside. RNAi technique has become a powerful tool for basic research to selectively knock down gene expression in vitro and in vivo. Our scientific and industrial communities have started to develop RNAi therapeutics as the next class of drugs for treating a variety of genetic disorders, such as cancer and other diseases that are particularly hard to address with current treatment strategies.Key Featuresa Providesa insighta intoa thea currenta advancesa anda hurdlesa ofa RNAia therapeutics.a a Acceleratesa RNAi,a miRNAs, and siRNAa druga developmenta for cancer therapya froma bencha toa bedside.a Addressesa various modifications anda novela deliverya strategies for miRNAs,a piRNAsa and siRNA deliverya ina anticancer therapeutics.a a Explores the need for the interactiona ofa hematologists,cella biologists,a immunologists, and materiala scientistsa in the development of a novela cancer therapies.a Describes thea current statusa of clinical trials related to miRNA and siRNA-based cancer therapya Presentsa remaining issues that need to be overcome to establisha successful therapies.a
